Type 2 Diabetes

Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.

Data from the BRAVES trial indicates 70% of patients undergoing metabolic or bariatric surgery with histologically confirmed NASH achieved resolution at 52 weeks.

An analysis of adults with T2D found a higher intake of sugar-sweetened beverages was associated with higher all-cause mortality and CVD incidence, whereas healthier beverage options were inversely associated with all-cause mortality.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.

Many effective anti-obesity medications could be manufactured and sold profitably for a low price, with estimated minimum prices up to 20-fold cheaper than current prices in some countries.

A new study leveraging data from 184 countries based on 11 dietary factors provides an overview of the diet attributable burden of type 2 diabetes in the world today.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

Announced on April 14, the clearance allows for FreeStyle Libre 3 users to obtain real-time glucose readings on a large, easy-to-see screen directly from their back of arm sensors.

A new analysis suggests an association between elevated heart rate and increased risk of developing new-onset T2D, but the effects were largely restricted to younger individuals.

A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.

Compared with individuals with normal glycemic status, a recent analysis found AMD risk increased with higher glycemic status and longer duration of diabetes.

A prospective study of more than 120 patients who underwent bariatric surgery sheds additional light on the potential benefits incurred by undergoing weight loss surgery in people with obesity.

Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.

A systematic review and meta-analysis found the prevalence of diabetes increases with COVID-19 severity, with diabetes accounting for 9.5% of severe COVID-19 cases and 16.8% of deaths.

Our March 2023 endocrine month in review highlights the top news and headlines in endocrinology from the past month, including reductions in insulin list prices, regulatory decisions, and more!

Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

In this episode, hosts celebrate the 10-year anniversary of the approval of the first SGLT2 inhibitor, discuss announcements related to insulin pricing, and take a deep dive into 24-week data from the MOMENTUM trial.

Our latest endocrine case report from Brady Pregerson, MD, features a patient in their mid-70s with a history of diabetes mellitus and end-stage kidney disease presenting with 6 days of gradually worsening right ear pain. Can you determine the correct diagnosis?

A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis for forthcoming phase 3 research examining the agent.

A systematic review and meta-analysis of 27 studies reveal the prevalence of DR in pediatric T2D increased significantly more than 5 years after diagnosis.

In this in-studio episode, hosts offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes and take a deep dive into a recent announcement of an FDA clearance for Abbott's FreeStyle Libre sensors.

New research indicates cooccurring edentulism and diabetes mellitus were linked to accelerated cognitive decline among participants in a nationally representative sample of older adults.

Data from a phase 2 randomized clinical trial demonstrate use of the GLP-1 receptor agonist exenatide could be used as a treatment for idiopathic intracranial hypertension in women.

If approved, Boehringer Ingelheim and Eli Lilly and Company's SGLT2 inhibitor would be the first agent in the class with an indication as an adjunct to diet and exercise for improving glycemic control in children with type 2 diabetes aged 10 years and older.